Employees: 4,218
Size Aarti Pharmalabs (AARTIPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $984M, the 608th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,013 on 18 Nov 2026.
Performance Over six months the shares gained 43.6%, against -17.5% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 13.4% over the last twelve months (peer median +5.7%); the operating margin is 17.7% (peer median 12.5%).
Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.3× (6th most expensive of 19).
Capital Return on invested capital runs 3.7 points below its cost of capital (12.9% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹21.6B | ₹17.9B | ₹20.9B | ₹18.2B | ₹19.4B |
| Revenue growth | — | -14% | +15% | -6% | — |
| Gross profit | ₹8.59B | ₹4.93B | ₹5.94B | ₹3.93B | ₹4.07B |
| EBITDA | ₹5.00B | ₹3.81B | ₹4.42B | ₹3.55B | ₹3.36B |
| Net income | ₹2.57B | ₹1.75B | ₹2.72B | ₹2.17B | ₹1.93B |
| Free cash flow | n/a | -₹1.84B | -₹893M | ₹466M | ₹1.28B |
| Capital expenditure | n/a | ₹4.48B | ₹4.44B | ₹1.99B | ₹1.20B |
| Total debt | ₹8.97B | ₹7.54B | ₹4.13B | ₹2.85B | ₹2.15B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AARTIPHARM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.8% | -9.0% | 2nd highest of 21 |
| 6-month return | +43.6% | -17.5% | 2nd highest of 21 |
| Distance from 52-week high | -3.2% | -39.2% | highest of 21 |
| Revenue growth (TTM) | +13.4% | +5.7% | 7th highest of 19 |
| Operating margin | 17.7% | 12.5% | 4th highest of 19 |
| EV / Sales | 4.7× | 3.3× | 6th most expensive of 19 |
| ROIC minus cost of capital | -3.7 pp | +0.1 pp | 3rd lowest of 19 |
| EV / EBITDA | 20.1× | 11.1× | 2nd most expensive of 6 |
| Net debt / EBITDA | 1.8× | 2.1× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | 4.7× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | 75.0× | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 1.3× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 6.3× | 5.6% | +9.3% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 1.4× | 2.3% | +1.8% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 5.4× | 17.7% | +27.3% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 5.2× | 12.7% | +19.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 4.2× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | 19.3× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 1.3× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 0.9× | -10.7% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 2.3× | 4.3% | +3.5% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 4.0× | 7.5% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 4.2× | 4.4% | +7.7% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |